Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Toshihiko Doi(National Cancer Center Hospital East)
Cited by 108